Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 25;137(8):1120-1124.
doi: 10.1182/blood.2020007236.

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A Ollila  1   2 , Habibe Kurt  2   3 , Jozal Waroich  2   4 , John Vatkevich  1 , Ashlee Sturtevant  3 , Nimesh R Patel  2   3 , Patrycja M Dubielecka  1   2 , Diana O Treaba  2   3 , Adam J Olszewski  1   2
Affiliations

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A Ollila et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
Clinicopathologic characteristics, mutations, and prevalence by lymphoma subtypes. (A) Clinicopathologic characteristics and mutations in patients with CNS or systemic (non-CNS) recurrence of DLBCL. Tumors were grouped into genomic subtypes according to the LymphGen classifier and hc. Boxes list definitions of the hc subgroups, and respective clusters are highlighted in the heatmap; only genes mutated in >10% patients are included. (B) Prevalence of mutated genes in groups with CNS or systemic (non-CNS) recurrence. Only genes mutated in >10% patients are included; no single gene was associated with CNS recurrence after adjustment for multiple testing. (C) Time from diagnosis to progression, stratified by type of recurrence. Median time to recurrence was 10 months (95% confidence interval, 8-11) and did not significantly differ between groups (log-rank P = .70). (D) Overall survival after recurrence. Median survival was shorter for patients with CNS recurrence (6 vs 17 months), but the difference was not statistically significant (log-rank P = .21). (E) Comparison of prevalence of specific LymphGen-determined DLBCL subtypes between patients with CNS or systemic-only (Sys) recurrence and unselected (Uns) DLBCL cases from 2 aggregated cohorts (N = 462),,; the MCD subtype was significantly more prevalent among patients with CNS recurrence (38% vs 8%, P = .003), whereas no CNS-relapsed tumor classified as ST2 or BN2 subtype. (F) Comparison of DLBCL subtypes defined by the hc between patients with CNS or systemic-only (Sys) recurrence and unselected DLBCL cases (Uns); the hc-MCD subtype was significantly more prevalent in tumors with CNS recurrence (46% vs 17%, P = .017), whereas other subtypes did not differ between groups.
See this image and copyright information in PMC

Comment in

References

    1. Schmitz N, Zeynalova S, Nickelsen M, et al. . CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-3156. - PubMed
    1. Gleeson M, Counsell N, Cunningham D, et al. . Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516. - PMC - PubMed
    1. Bartlett NL, Wilson WH, Jung SH, et al. . Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799. - PMC - PubMed
    1. Klanova M, Sehn LH, Bence-Bruckler I, et al. . Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926. - PMC - PubMed
    1. Savage KJ, Slack GW, Mottok A, et al. . Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182-2188. - PubMed

Publication types

LinkOut - more resources